All In Biotech

Drug Trial Radar · NCT00317707

Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk

Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk

Last checked: Nov 20, 2026Latest source record: Jan 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,513 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,513

Actual

Start

Feb 2004

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the everyday practice cardiovascular prevention in people at high risk is still unsatisfactory and treatments with documented efficacy are generally under-used. Polyunsaturated fatty acids of marine origin (n-3 PUFA) are the latest more promising strategy to improve prognosis in these patients. The Risk and Prevention study combines an epidemiological and an experimental approach in order to: 1. Verify the possibility to optimise cardiovascular prevention in subjects at high risk by planning the intervention with patients and setting individual goals (outcome study) 2. Evaluate the efficacy of a long term n-3 PUFA treatment in reducing the incidence of cardiovascular events, through a controlled, randomised, double blind clinical trial.

Conditions

  • Cardiovascular Diseases

Interventions

  • N-3 Polyunsaturated Fatty AcidsDrug

    Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA

  • Placebo: Olive oilDrug

    Each subject assigned to the control group will receive 1 g/day capsule of olive oil.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. cardiovascular deaths and hospitalization for cardiovascular causesTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mario Negri Institute for Pharmacological Research

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.